Hims & Hers to offer unapproved peptides after US eases curbs
Hims & Hers to offer unapproved peptides after US eases curbs Reuters
Covered in this story
Analyst targets on Hims Hers Health Inc Class a
- Truist Securities: at $28.5 · target $32 by Oct 2027 · Hold via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $HIMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Hims Hers Health Inc Class a →Dalsna Finance is currently tracking 5 stories mentioning Hims Hers Health Inc Class a, the earliest published 9 Nov 2026.
Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.